CDX2 and colorectal cancer: In the TCGA cohort, the CDX2-suppressed (CDX2 log RNA Seq V2 < −2) group of colorectal cancers consisted of 75 cases (12.6% of the entire TCGA colorectal cancer cohort) and the non-CDX2-suppressed (CDX2 log RNA Seq V2 > 0) group consisted of 249 cases (41.9% of the entire TCGA cohort).